Loading companies…
BB
BrainChild Bio
United States · Biotech
BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma.
Product and customers
Its approach engineers immune cells to target tumor antigens and delivers repeat infusions locally into cerebrospinal fluid through an implanted reservoir, aiming to reach tumors behind the blood-brain barrier. The company is clinical-stage, with BCB-276 in a Phase 2 study and additional candidates in development.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $116M | Participants not disclosed |
Investors
No participants disclosed.
Coverage
Sep 8, 2026BrainChild Bio · Series ASimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed